Results 101 to 110 of about 25,852 (227)

MYCN Amplification in RB1‐Inactivated Retinoblastoma: Association With High‐Risk Features

Pediatric Blood &Cancer, Volume 73, Issue 6, June 2026.
ABSTRACT Background MYCN amplification occurs in a subset of retinoblastoma cases, both with and without RB1 inactivation. It has been suggested that retinoblastomas with MYCN amplification represent a distinct entity with more aggressive clinical behavior.
Kyriaki Papaioannou, Regina Kubica, Karen Fischhuber, Jasmin Beygo, Madlen Reschke, Petra Ritter‐Sovinz, Eva Biewald, Petra Ketteler, Dietmar Lohmann, Deniz Kanber   +9 more
wiley   +1 more source

Prospective Randomized Trial of Melphalan and Prednisone Versus Vincristine, Carmustine, Melphalan, Cyclophosphamide, and Prednisone in the Treatment of Primary Systemic Amyloidosis

, 1999
PURPOSE: Primary systemic amyloidosis is an immunoglobulin deposition disorder in which insoluble light chains cause organ dysfunction and death. The established conventional therapy is treatment with melphalan and prednisone.
Thomas E. Witzig, Robert A. Kyle, Philip R. Greipp, John A. Lust, Martha Q. Lacy, Morie A. Gertz   +5 more
core   +1 more source

Integrating Oncolytic Virus Engineering and Delivery Strategies for Enhanced Cancer Virotherapy

Aggregate, Volume 7, Issue 6, June 2026.
Integrated engineering strategies combining oncolytic virus (OV) design with advanced delivery platforms overcome biological barriers and enhance cancer virotherapy. Genetic engineering improves viral potency and selectivity, while local and systemic delivery systems promote viral protection, tumor targeting, penetration, and tumor microenvironment ...
Jiliang Zhao, Dong Wang, Lei Wang, Hongkai Zhang, Yue Sun, Dan Ding   +5 more
wiley   +1 more source

Preclinical Studies of the Melphalan Prodrug J1 for Cancer Therapy

, 2007
J1 (L-melphalanyl-L-p-fluorophenylalanyl ethyl ester) is a dipeptide derivative of the alkylating agent melphalan with increased cytotoxicity. In this thesis the preclinical pharmacology of J1 has been characterized.
Wickström, Malin
core  

Proline prodrug of melphalan, prophalan-l, demonstrates high therapeutic index in a murine melanoma model

, 2007
The therapeutic efficacy of prophalan-l, the l-proline prodrug of melphalan that demonstrated prolidase-dependent bioactivation to melphalan, was examined in vivo in a mouse melanoma model.
Lee, Kyung Dall, Amidon, Gordon L., Landowski, Christopher P.; id_orcid, Mittal, Sachin, Tsume, Yasuhiro, Hilfinger, John M.   +5 more
core   +1 more source

Immunopotentiation by low-dose melphalan therapy.

, 1992
Immunopotentiation by low-dose melphalan ...
Mary Margaret. Bartik (7967666)
core  

A reduced-toxicity myeloablative conditioning approach for hematopoietic cell transplant in juvenile myelomonocytic leukemia

Frontiers in Oncology
IntroductionAllogeneic hematopoietic cell transplantation (HCT) is a potentially curative treatment for most children with juvenile myelomonocytic leukemia (JMML), but overall survival remains poor at 50%. Given its rarity and heterogeneity, there is no
Eman Elsabagh, Rachel Gallant, Lior Goldberg, Aditya Sharma, Paul L. Martin, Timothy A. Driscoll, Andrea Bauchat, Joanne Kurtzberg, LaTarsha Spencer, Paibel I. Aguayo-Hiraldo, Neena Kapoor, Kris M. Mahadeo, Hisham Abdel-Azim   +12 more
doaj   +1 more source

BCMA CAR T for AL Amyloidosis After Plasmacytic Relapse of Lymphoplasmacytic Lymphoma

eJHaem, Volume 7, Issue 3, June 2026.
ABSTRACT Introduction Lambda immunoglobulin light chain (AL) amyloidosis associated with non‐IgM lymphoplasmacytic lymphoma (LPL) is rare and often refractory to conventional therapies. Treatment options for relapsed disease remain limited. Methods Here we describe the case of a patient with a history of LPL‐associated AL amyloidosis who had previously
Nadia Al Haddad, Eugene Brailovski, Jacqueline Dela‐Pena, Melinda Cook, Michael Rosenzweig, Heather Jolie Landau   +5 more
wiley   +1 more source

Therapeutic Options for IgA Pemphigus in Patients Refractory to Dapsone

JEADV Clinical Practice, Volume 5, Issue 2, Page 415-424, June 2026.
ABSTRACT IgA pemphigus is a rare autoimmune blistering disorder with limited therapeutic guidance available due to its rarity and complex presentation. This comprehensive analysis evaluates the therapeutic outcomes of 67 published patients, emphasising the significant role of dapsone as the first‐line treatment.
Lorenz Frasheri, Marta Dechant, Tilo Biedermann   +2 more
wiley   +1 more source

Tissue and perfusate pharmacokinetics of melphalan in isolated perfused rat hindlimb

, 1997
Melphalan is commonly used as a cytotoxic agent in isolated limb perfusion for locally recurrent malignant melanoma. The time course of melphalan concentrations in perfusate and tissues during a 60-min melphalan perfusion and 30-min drug-free washout in ...
Smithers, BM, Wu, ZY, Roberts, MS
core